Juno Therapeutics Inc. (NASDAQ:JUNO) belonging to the Medical sector has declined -3.32% and closed its last trading session at $18.95.
The company reported its EPS on 11/09/2016. Currently, the stock has a 1 Year Price Target of $32.58.
The consensus recommendation, according to Zacks Investment research, is 2.4. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.9 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.78 and 1.63 respectively.
Juno Therapeutics Inc. on 11/09/2016 reported its EPS as $-0.57 with the analysts projecting the EPS of the stock as $-0.55. The company beat the analyst EPS Estimate with the difference of $-0.02. This shows a surprise factor of -3.6%.
Many analysts have provided their estimated foresights on Juno Therapeutics Inc. Earnings, with 8 analysts believing the company would generate an Average Estimate of $-0.59. Whereas they predicted High and Low Earnings Estimate as $-0.06 and $-0.79 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.53.
Analysts are also projecting an Average Revenue Estimate for Juno Therapeutics Inc. as $13.96 Million in the Current Quarter. This estimate is provided by 9 analysts. The High Revenue estimate is predicted as 20.3 Million, while the Low Revenue Estimate prediction stands at 7.5 Million. The company’s last year sales total was 4.15 Million.
The Company got Downgrade by Raymond James on 6-Dec-16 from Outperform to Mkt Perform.
Insider Trades for Juno Therapeutics Inc. show that the latest trade was made on 9 Nov 2016 where Azelby (Robert), the Officer completed a transaction type “Sell” in which 12921 shares were traded at a price of $24.14.
13 Insider Sales transactions were made totaling 1791420 shares traded.
12 analysts projected Price Targets for Juno Therapeutics Inc.. The analysts believe that the company stock price could grow as high as $41. The Low Price target projection by analysts is $23 and the Mean Price Target is $31.75.
Juno Therapeutics Inc. (NASDAQ:JUNO) has the market capitalization of $1.95 Billion. The company rocked its 52-Week High of $49.72 on Jun 6, 2016 and touched its 52-Week Low of $18.72 on Dec 6, 2016. The stock has Return on Assets (ROA) of -19 percent. Return on Equity (ROE) stands at -24% and Return on Investment (ROI) of -20.3 percent.
The stock is currently showing YTD performance of -56.9 Percent. The company has Beta Value of 0 and ATR value of 1.85. The Weekly and Monthly Volatility stands at 7.03% and 6.82%.
Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.